SCHEMBL6887065

SCHEMBL6887065

CC1CCCCC(C)[N]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL240621 0.92
SCHEMBL486074 0.92
SCHEMBL6369964 0.84
SCHEMBL2784496 0.84
SCHEMBL522287 0.84
SCHEMBL2784494 0.84
SCHEMBL2784951 0.84
SCHEMBL6398036 0.74
SCHEMBL11621944 0.70
SCHEMBL43289 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244611-B1 SQUARIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS CELLTECH R&D LTD (GB) 2004-06-30 EP disclosed
US-6740654-B2 INHIBIT THE BINDING OF INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS, OR DISORDERS INVOLVING THE INAPPROPRIATE GROWTH OR MIGRATION OF CELLS. CELLTECH R & D LIMITED (GB) 2004-05-25 US disclosed
EP-1337534-A1 3-SUBSTITUTED 2,7-NAPHTHYRIDIN-1-YL DERIVATIVES Celltech R &amp; D Limited (GB) 2003-08-27 EP disclosed
US-6593338-B2 Inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells. CELLTECH R&D LIMITED (GB) 2003-07-15 US disclosed
EP-1301488-A1 SQUARIC ACID DERIVATIVES CONTAINING A BICYCLIC HETEROAROMATIC RING AS INTEGRIN ANTAGONISTS Celltech R&amp;D Limited (GB) 2003-04-16 EP disclosed
US-6545013-B2 Of squaric acids; inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells. CELLTECH R&D LIMITED (GB) 2003-04-08 US disclosed
EP-1286995-A1 2,7-NAPHTHYRIDINE DERIVATIVES Celltech R&amp;D Limited (GB) 2003-03-05 EP disclosed
EP-1284967-A1 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES Celltech R&amp;D Limited (GB) 2003-02-26 EP disclosed
US-20020177605-A1 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES CELLTECH R&D, LTD. (GB) 2002-11-28 US disclosed
US-6469025-B1 FOR THE PROPHYLAXIS OR TREATMENT OF A DISEASE OR DISORDER IN A MAMMAL IN WHICH THE EXTRAVASATION OF LEUKOCYTES PLAYS A ROLE; INHIBITING THE BINDING OF ALPHA 4 INTEGRINS TO THEIR LIGANDS CELLTECH R&D LTD. (GB) 2002-10-22 US disclosed
US-20020115684-A1 2, 7-naphthyridine derivatives CELLTECH R&D, LTD. (GB) 2002-08-22 US disclosed
US-20020107263-A1 Squaric acid derivatives CELLTECH R&D, LTD. (GB) 2002-08-08 US disclosed
US-6403608-B1 ANTIINFLAMMATORY AND IMMUNE DISORDERS CELLTECH R&D, LTD. (GB) 2002-06-11 US disclosed
WO-2002042264-A1 3-SUBSTITUTED 2,7-NAPHTHYRIDIN-1-YL DERIVATIVES CELLTECH R & D LIMITED (GB) 2002-05-30 WO disclosed
WO-2002004426-A1 SQUARIC ACID DERIVATIVES CONTAINING A BICYCLIC HETEROAROMATIC RING AS INTEGRIN ANTAGONISTS CELLTECH R & D LIMITED (GB) 2002-01-17 WO disclosed
WO-2001092256-A1 2,7-NAPHTHYRIDINE DERIVATIVES CELLTECH R & D LIMITED (GB) 2001-12-06 WO disclosed
WO-2001092233-A1 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES CELLTECH R & D LIMITED (GB) 2001-12-06 WO disclosed
US-20010020017-A1 Squaric acid derivatives CELLTECH R&D LIMITED (GB) 2001-09-06 US disclosed
WO-2001047867-A1 SQUARIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS CELLTECH R & D LIMITED (GB) 2001-07-05 WO disclosed
US-4009208-A N,N'-HEPTAMETHYLENEBIS(4-METHOXYBENZAMIDE) STERLING DRUG INC. (US) 1977-02-22 US disclosed